Common Contracts
4 similar Common Stock Purchase Agreement contracts by Gilead Sciences, Inc., Arcus Biosciences, Inc., Gilead Sciences Inc
= CERTAIN INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS OF THE TYPE THAT THE REPORTING PERSON CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL ARCUS BIOSCIENCES, INC. THIRD AMENDED AND RESTATED COMMON STOCK PURCHASE...Common Stock Purchase Agreement • January 31st, 2024 • Gilead Sciences, Inc. • Biological products, (no disgnostic substances) • New York
This Third Amended and Restated Common Stock Purchase Agreement (this “Agreement”) is dated as of January 29, 2024, by and between Arcus Biosciences, Inc., a Delaware corporation (the “Company”), and Gilead Sciences, Inc., a Delaware corporation (“Gilead”). This Agreement amends and restates in its entirety the Second Amended and Restated Common Stock Purchase Agreement entered into between the Company and Gilead on June 27, 2023 (the “Existing Purchase Agreement”), which amended the Common Stock Purchase Agreement, dated May 27, 2020, by and between the Company and Gilead (the “Original Agreement”), as previously amended and restated on January 31, 2021.
= CERTAIN INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS OF THE TYPE THAT THE REPORTING PERSON CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL ARCUS BIOSCIENCES, INC. SECOND AMENDED AND RESTATED COMMON STOCK PURCHASE...Common Stock Purchase Agreement • July 6th, 2023 • Gilead Sciences, Inc. • Biological products, (no disgnostic substances) • New York
This Second Amended and Restated Common Stock Purchase Agreement (this “Agreement”) is dated as of June 27, 2023, by and between Arcus Biosciences, Inc., a Delaware corporation (the “Company”), and Gilead Sciences, Inc., a Delaware corporation (“Gilead”). This Agreement amends and restates in its entirety the Amended and Restated Common Stock Purchase Agreement previously entered into between the Company and Gilead dated as of January 31, 2021, which amended the Common Stock Purchase Agreement previously entered into between the Company and Gilead dated as of May 27, 2020 (the “Original Agreement”).
= CERTAIN INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY SENSITIVE IF PUBLICLY DISCLOSED ARCUS BIOSCIENCES, INC. AMENDED AND RESTATED COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • February 2nd, 2021 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • New York
This Amended and Restated Common Stock Purchase Agreement (this “Agreement”) is dated as of January 31, 2021, by and between Arcus Biosciences, Inc., a Delaware corporation (the “Company”), and Gilead Sciences, Inc., a Delaware corporation (“Gilead”). This Agreement amends and restates in its entirety the Common Stock Purchase Agreement originally entered into between the Company and Gilead as of May 27, 2020.
= CERTAIN INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ARCUS BIOSCIENCES, INC. COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • July 13th, 2020 • Arcus Biosciences, Inc. • Pharmaceutical preparations • New York
This Common Stock Purchase Agreement (this “Agreement”) is dated as of May 27, 2020, by and between Arcus Biosciences, Inc., a Delaware corporation (the “Company”), and Gilead Sciences, Inc., a Delaware corporation (“Gilead”).
